Kleber F X, Thyroff-Friesinger U
Academic Teaching Hospital, Munich, FRG.
Cardiology. 1990;77 Suppl 5:67-74. doi: 10.1159/000174699.
This multicentre, double-blind, double-dummy, randomised parallel group study in 247 patients with mild chronic congestive heart failure compared the efficacy and tolerability of ibopamine, hydrochlorothiazide (HCTZ), ibopamine plus HCTZ and placebo during an 8-week treatment period. The combination of ibopamine and HCTZ resulted in a significantly greater reduction in body weight (p less than 0.05) than HCTZ alone. Trends in favour of the combination as compared to ibopamine or HCTZ alone and in favour of ibopamine as compared to HCTZ were observed. All active treatments were superior to placebo. All active treatments were well tolerated. There was a trend towards a higher incidence of hypokalemia in patients treated with HCTZ, alone or in combination, compared to those receiving ibopamine alone or placebo.
这项针对247例轻度慢性充血性心力衰竭患者的多中心、双盲、双模拟、随机平行组研究，比较了异波帕胺、氢氯噻嗪（HCTZ）、异波帕胺加HCTZ以及安慰剂在8周治疗期内的疗效和耐受性。与单独使用HCTZ相比，异波帕胺与HCTZ联合使用导致体重显著降低（p<0.05）。观察到联合用药组相比于单独使用异波帕胺或HCTZ有优势的趋势，以及异波帕胺相比于HCTZ有优势的趋势。所有活性治疗均优于安慰剂。所有活性治疗的耐受性良好。与单独接受异波帕胺或安慰剂治疗的患者相比，单独或联合使用HCTZ治疗的患者低钾血症发生率有升高趋势。
